Ocugen, Inc.
(NASDAQ : OCGN)

( )
OCGN After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 6.42%282.350.0%$4047.51m
BNTXBioNTech SE 8.17%302.690.0%$1321.33m
NVAXNovavax, Inc. 28.90%182.8578.2%$874.24m
AMGNAmgen, Inc. 1.21%211.321.4%$643.80m
GILDGilead Sciences, Inc. 0.22%69.651.0%$510.30m
LGVNLongeveron Inc. -3.31%19.580.0%$453.36m
VRTXVertex Pharmaceuticals, Inc. 0.08%205.221.9%$451.66m
REGNRegeneron Pharmaceuticals, Inc. 1.61%635.092.7%$406.05m
ILMNIllumina, Inc. 5.06%369.433.3%$341.03m
SNSSSunesis Pharmaceuticals, Inc. 2.38%4.310.7%$301.28m
BIIBBiogen, Inc. 1.21%226.831.8%$284.75m
SGENSeagen Inc. 0.30%146.445.8%$152.49m
INCYIncyte Corp. 2.65%66.732.4%$150.12m
EXASEXACT Sciences Corp. 3.12%83.3618.0%$145.51m
BMRNBioMarin Pharmaceutical, Inc. 2.23%86.124.2%$137.03m

Company Profile

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.